SEP 19, 2018
Intraocular Drug Delivery Systems
Glaucoma Subspecialty Day 2017
06:12
Glaucoma
Dr. Jonathan Myers discusses sustained-release drug delivery, which has the potential to eliminate compliance problems. Additionally, intraocular delivery might reduce topical side effects and allow much lower total dosages of medication. Currently, there are no FDA-approved sustained-release drug delivery systems for glaucoma, although the pilocarpine Ocusert was marketed in the past. Dr. Myers discusses a bimatoprost sustained-release implant (Allergan), a biodegradable polymer drug delivery system that uses an extended-release formulation of travoprost (ENV515; Envisia), and an intravitreal microparticle formulation of dorzolamide (GreyBug).